Polymorphisms in candidate genes: implications for the current treatment of Parkinson's disease.
Pharmacological treatment remains the cornerstone of therapy in Parkinson's disease. A number of clinical and genetic factors may influence the therapeutic response and treatment-related complications. Some exploratory studies have suggested that genetic polymorphisms may influence an individual's response to dopaminergic therapy and susceptibility to drug-related complications, such as hallucinations, dyskinesias, motor fluctuations and sudden onset of sleep episodes. This article provides a concise summary and discussion of the potential utility and limitation of studies that have examined the influence of genetic polymorphisms on drug-related response and complications in Parkinson's disease.
Skipper
Lisa
L
Population Genetics, Genome Institute of Singapore, Singapore.
Liu
Jian-Jun
JJ
Tan
Eng-King
EK
D000818:Animals; D000978:Antiparkinson Agents / Q000627:therapeutic use*; D014644:Genetic Variation / Q000235:genetics; D006801:Humans; D010300:Parkinson Disease / Q000188:drug therapy* / Q000235:genetics*; D011110:Polymorphism, Genetic / Q000235:genetics*
D000978:Antiparkinson Agents